Vontobel Holding Ltd. lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 75.2% in ...

Since then, Alnylam has claimed approval for two more RNAis, Givlaari (givosiran) for acute hepatic porphyria (AHP) and Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1). RNAi uses small ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target upped by Morgan Stanley from $275.00 to $284.00 in a research note issued to investors on Friday,Benzinga reports. Morgan ...

It also relates to the early stage givosiran for acute hepatic porphyrias, Silence Therapeutics said. There is no suggestion that Alnylam and The Medicines Company acquired intellectual property ...

Red light therapy involves shining specific wavelengths of light on the skin and cells. It is thought to help the production of mitochondria and give the ...

A diet low in fat and fiber, taken in small, frequent meals, has been advocated, although different diets have not been rigorously compared in patients with gastroparesis. Nutrient liquids might ...